Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICAL-Teens-TP: Enoxaparin for VTE Prophylaxis in Critically Ill Adolescents
NCT06628778Phase 3Not yet recruiting
- Sponsor
- Johns Hopkins All Children's Hospital
- Start
- Apr 2027
- Primary completion
- Apr 2034
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Johns Hopkins All Children's Hospital. Primary endpoints: Symptomatic venous thromboembolism and Clinically relevant bleeding. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06628778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628778.